Vir Biotechnology (VIR) Expected to Announce Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is projected to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Vir Biotechnology to post earnings of $0.3336 per share and revenue of $135.8820 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.84). The company had revenue of ($0.03) million during the quarter, compared to analysts’ expectations of $55.49 million. Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.During the same period in the prior year, the firm earned ($0.88) EPS. On average, analysts expect Vir Biotechnology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $8.85 on Wednesday. The company’s fifty day moving average price is $9.35 and its 200-day moving average price is $8.91. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -2.83 and a beta of 1.62. Vir Biotechnology has a one year low of $4.16 and a one year high of $11.66.

Insiders Place Their Bets

In related news, Director Janet Napolitano sold 3,200 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the sale, the director directly owned 21,216 shares in the company, valued at $200,491.20. This represents a 13.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Vicki L. Sato sold 22,000 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $10.05, for a total transaction of $221,100.00. Following the sale, the director directly owned 1,078,391 shares of the company’s stock, valued at $10,837,829.55. The trade was a 2.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,579 shares of company stock valued at $254,922 over the last quarter. 2.90% of the stock is currently owned by company insiders.

Institutional Trading of Vir Biotechnology

A number of institutional investors have recently modified their holdings of VIR. GSK plc bought a new stake in shares of Vir Biotechnology in the fourth quarter worth about $51,562,000. Balyasny Asset Management L.P. bought a new stake in shares of Vir Biotechnology in the 4th quarter worth approximately $8,252,000. State Street Corp grew its position in shares of Vir Biotechnology by 18.9% in the 4th quarter. State Street Corp now owns 6,229,555 shares of the company’s stock worth $37,564,000 after buying an additional 988,262 shares during the last quarter. Millennium Management LLC increased its stake in shares of Vir Biotechnology by 129.2% during the third quarter. Millennium Management LLC now owns 1,396,504 shares of the company’s stock valued at $7,974,000 after buying an additional 787,212 shares during the period. Finally, HRT Financial LP raised its holdings in shares of Vir Biotechnology by 234.7% during the fourth quarter. HRT Financial LP now owns 591,648 shares of the company’s stock valued at $3,567,000 after acquiring an additional 414,864 shares in the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on VIR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. Morgan Stanley lifted their price target on Vir Biotechnology from $23.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, June 11th. Leerink Partners increased their price objective on Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a research report on Wednesday, June 3rd. Finally, Wall Street Zen cut Vir Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.